Ipsen reports H1 total sales growth of 11.4% at CER, driven by Rare Disease, Neuroscience, and Oncology. H1 core operating income is €656m, up 21.9%. FY 2025 guidance upgraded to total-sales growth >7.0% at CER and core operating margin >32.0%. Pipeline progress includes tovorafenib filing in Europe and LANT Phase II trial initiation in cervical dystonia.

European Commission approves Cabometyx® for advanced neuroendocrine tumors. Key upcoming milestones include FALKON trial results for fidrisertib in FOP and LANT proof-of-concept data in aesthetics. Ipsen’s financial results reflect strong growth and momentum across all therapeutic areas. Guidance includes potential negative impact on Somatuline sales due to generic competition.

Ipsen’s pipeline progresses with Phase II study of LANT in cervical dystonia. The company received European Commission approval for Cabometyx® in advanced neuroendocrine tumors. Ipsen’s financial guidance for 2025 is upgraded to total-sales growth >7.0% at CER and core operating margin >32.0%. Quarterly sales update scheduled for October 22, 2025.

Read more at GlobeNewswire: Ipsen delivers strong results in the first half of 2025 and